Atlas Trials

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Clinical trial NCT03916744 · COMPLETED

Trial details

NCT number
NCT03916744
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2019-07-26
Primary completion
2021-05-25
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.